Sulopenem/probenecid

Last updated

Sulopenem/probenecid
Combination of
Sulopenem Penem antibacterial
Probenecid Renal tubular transport inhibitor
Clinical data
Trade names Orlynvah
License data
Routes of
administration 		By mouth
ATC code
  • None
Legal status
Legal status
Identifiers
KEGG

Sulopenem/probenecid, sold under the brand name Orlynvah, is a fixed-dose combination medication used for the treatment of urinary tract infections. [1] It contains sulopenem, a penem antibacterial, as the prodrug sulopenem etzadroxil; and probenecid, a renal tubular transport inhibitor. [1]

Contents

The most common side effects include diarrhea, nausea, vaginal yeast infection, headache, and vomiting. [3]

The combination was approved for medical use in the United States in October 2024. [1] [3] [4] [5] [6]

Medical uses

Sulopenem/probenecid is indicated for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli , Klebsiella pneumoniae , or Proteus mirabilis in adult women who have limited or no alternative oral antibacterial treatment options. [1] [3]

Contraindications

Sulopenem/probenecid is contraindicated in people with a history of hypersensitivity reactions to sulopenem etzadroxil or probenecid or other beta-lactam antibacterial drugs; people with known blood dyscrasias; people with known uric acid kidney stones; and people who are also taking ketorolac tromethamine. [3]

Adverse effects

The US Food and Drug Administration (FDA) prescribing information for sulopenem/probenecid includes warnings for hypersensitivity reactions, Clostridioides difficile-associated diarrhea, and potential exacerbation of gout when given to people with a known history of gout. [3]

History

The effectiveness of sulopenem/probenecid was evaluated in two phase III controlled, randomized, double blind clinical trials (trial 1 and trial 2) which enrolled adult women with uncomplicated urinary tract infections. [3] Trial 1 (NCT05584657) was a noninferiority trial in which 2214 adult women with uncomplicated urinary tract infections were randomized and treated. [3] Sulopenem/probenecid demonstrated efficacy in participants with amoxicillin/clavulanate-susceptible pathogens with a composite response rate (combined microbiological response and clinical response) of 62% compared to a composite response rate of 55% in the amoxicillin/clavulanate group. [3] Trial 2 (NCT03354598) was a noninferiority trial in which 1660 adult women with uncomplicated urinary tract infections were randomized and treated. [3] Sulopenem/probenecid demonstrated efficacy in participants with ciprofloxacin-resistant pathogens with a composite response rate of 48% compared to a composite response rate of 33% in the ciprofloxacin group. [3] Overall, in the two trials combined, 1932 participants were treated with sulopenem/probenecid. [3] Clinical trials evaluating sulopenem/probenecid for the treatment of participants with complicated urinary tract infections and complicated intra-abdominal infections did not demonstrate effectiveness. [3]

References

  1. 1 2 3 4 5 "Orlynvah (sulopenem etzadroxil and probenecid) tablets, for oral use" (PDF). Iterum Therapeutics. Archived (PDF) from the original on 26 October 2024.
  2. ↑ "Highlights of prescribing information - ORLYNVAHTM (sulopenem etzadroxil and probenecid) tablets, for oral use" (PDF). www.accessdata.fda.gov.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 "FDA approves new treatment for women with uncomplicated UTIs". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 26 October 2024. Retrieved 25 October 2024.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  4. ↑ "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Archived from the original on 19 April 2024. Retrieved 29 November 2024.
  5. ↑ New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  6. ↑ "Iterum Therapeutics Receives U.S. FDA Approval of Orlynvah (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections". Iterum Therapeutics (Press release). 25 October 2024. Retrieved 25 October 2024.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.